# Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant

> **NCT00388999** · PHASE1 · COMPLETED · sponsor: **Enzon Pharmaceuticals, Inc.** · enrollment: 46 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
- **DRUG:** Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
- **DRUG:** Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)

## Key facts

- **NCT ID:** NCT00388999
- **Lead sponsor:** Enzon Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2009-02
- **Final completion:** 2009-05
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2011-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00388999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00388999, "Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00388999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*